1
|
Chen H, Huang Z, Li J, Dong S, Xu Y, Ma S, Zhao J, Liu L, Sun T, Song W, Chen X. Hit-and-run vaccine system that overcomes limited neoantigen epitopes for efficient broad antitumor response. Sci Bull (Beijing) 2024; 69:922-932. [PMID: 38331707 DOI: 10.1016/j.scib.2024.01.039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2023] [Revised: 11/08/2023] [Accepted: 01/24/2024] [Indexed: 02/10/2024]
Abstract
Neoantigen cancer vaccines have been envisioned as one of the most promising means for cancer therapies. However, identifying neoantigens for tumor types with low tumor mutation burdens continues to limit the effectiveness of neoantigen vaccines. Herein, we proposed a "hit-and-run" vaccine strategy which primes T cells to attack tumor cells decorated with exogenous "neo-antigens". This vaccine strategy utilizes a peptide nanovaccine to elicit antigen-specific T cell responses after tumor-specific decoration with a nanocarrier containing the same peptide antigens. We demonstrated that a poly(2-oxazoline)s (POx) conjugated with OVA257-264 peptide through a matrix metalloprotease 2 (MMP-2) sensitive linker could efficiently and selectively decorate tumor cells with OVA peptides in vivo. Then, a POx-based nanovaccine containing OVA257-264 peptides to elicit OVA-specific T cell responses was designed. In combination with this hit-and-run vaccine system, an effective vaccine therapy was demonstrated across tumor types even without OVA antigen expression. This approach provides a promising and uniform vaccine strategy against tumors with a low tumor mutation burden.
Collapse
Affiliation(s)
- Hongyu Chen
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China; Key laboratory of Polymer Ecomaterials, Changchun Institue of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
| | - Zichao Huang
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China; Key laboratory of Polymer Ecomaterials, Changchun Institue of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
| | - Jiaxuan Li
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun 130021, China
| | - Si Dong
- Key laboratory of Polymer Ecomaterials, Changchun Institue of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
| | - Yudi Xu
- Key laboratory of Polymer Ecomaterials, Changchun Institue of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
| | - Sheng Ma
- Key laboratory of Polymer Ecomaterials, Changchun Institue of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China; Jilin Biomedical Polymers Engineering Laboratory, Changchun 130022, China
| | - Jiayu Zhao
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China; Key laboratory of Polymer Ecomaterials, Changchun Institue of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
| | - Liping Liu
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China; Key laboratory of Polymer Ecomaterials, Changchun Institue of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China
| | - Tianmeng Sun
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun 130021, China
| | - Wantong Song
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China; Key laboratory of Polymer Ecomaterials, Changchun Institue of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China; Jilin Biomedical Polymers Engineering Laboratory, Changchun 130022, China.
| | - Xuesi Chen
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China; Key laboratory of Polymer Ecomaterials, Changchun Institue of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China; Jilin Biomedical Polymers Engineering Laboratory, Changchun 130022, China.
| |
Collapse
|
2
|
Cong Z, Xiong Y, Lyu L, Fu B, Guo D, Sha Z, Yang B, Wu H. The relationship between Listeria infections and host immune responses: Listeriolysin O as a potential target. Biomed Pharmacother 2024; 171:116129. [PMID: 38194738 DOI: 10.1016/j.biopha.2024.116129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Revised: 12/31/2023] [Accepted: 01/02/2024] [Indexed: 01/11/2024] Open
Abstract
Listeria monocytogenes (Lm), a foodborne bacterium, can infect people and has a high fatality rate in immunocompromised individuals. Listeriolysin O (LLO), the primary virulence factor of Lm, is critical in regulating the pathogenicity of Lm. This review concludes that LLO may either directly or indirectly activate a number of host cell viral pathophysiology processes, such as apoptosis, pyroptosis, autophagy, necrosis and necroptosis. We describe the invasion of host cells by Lm and the subsequent removal of Lm by CD8 T cells and CD4 T cells upon receipt of the LLO epitopes from major histocompatibility complex class I (MHC-I) and major histocompatibility complex class II (MHC-II). The development of several LLO-based vaccines that make use of the pore-forming capabilities of LLO and the immune response of the host cells is then described. Finally, we conclude by outlining the several natural substances that have been shown to alter the three-dimensional conformation of LLO by binding to particular amino acid residues of LLO, which reduces LLO pathogenicity and may be a possible pharmacological treatment for Lm.
Collapse
Affiliation(s)
- Zixuan Cong
- School of Life Sciences, Chongqing University, Chongqing 401331, China
| | - Yan Xiong
- School of Life Sciences, Chongqing University, Chongqing 401331, China
| | - Lyu Lyu
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, China
| | - Beibei Fu
- School of Life Sciences, Chongqing University, Chongqing 401331, China
| | - Dong Guo
- School of Life Sciences, Chongqing University, Chongqing 401331, China
| | - Zhou Sha
- School of Life Sciences, Chongqing University, Chongqing 401331, China
| | - Bo Yang
- State Key Laboratory of Veterinary Etiological Biology, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu 730046, China.
| | - Haibo Wu
- School of Life Sciences, Chongqing University, Chongqing 401331, China.
| |
Collapse
|
3
|
Tabachnick-Cherny S, Pinto S, Berko D, Curato C, Wolf Y, Porat Z, Karmona R, Tirosh B, Jung S, Navon A. Polyglutamine-Related Aggregates Can Serve as a Potent Antigen Source for Cross-Presentation by Dendritic Cells. THE JOURNAL OF IMMUNOLOGY 2020; 205:2583-2594. [PMID: 33067378 DOI: 10.4049/jimmunol.1901535] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Accepted: 09/15/2020] [Indexed: 01/16/2023]
Abstract
Protective MHC class I-dependent immune responses require an overlap between repertoires of proteins directly presented on target cells and cross-presented by professional APC, specifically dendritic cells. How stable proteins that rely on defective ribosomal proteins for direct presentation are captured for cell-to-cell transfer remains enigmatic. In this study, we address this issue using a combination of in vitro (C57BL/6-derived mouse cell lines) and in vivo (C57BL/6 mouse strains) approaches involving stable and unstable versions of OVA model Ags displaying defective ribosomal protein-dependent and -independent Ag presentation, respectively. Apoptosis, but not necrosis, of donor cells was found associated with robust global protein aggregate formation and captured stable proteins permissive for cross-presentation. Potency of aggregates to serve as Ag source was directly demonstrated using polyglutamine-equipped model substrates. Collectively, our data implicate global protein aggregation in apoptotic cells as a mechanism that ensures the overlap between MHC class I epitopes presented directly or cross-presented by APC and demonstrate the unusual ability of dendritic cells to process stable protein aggregates.
Collapse
Affiliation(s)
- Shira Tabachnick-Cherny
- Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
| | - Sivan Pinto
- Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
| | - Dikla Berko
- Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
| | - Caterina Curato
- Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
| | - Yochai Wolf
- Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
| | - Ziv Porat
- Department of Biological Services, The Weizmann Institute of Science, Rehovot 76100, Israel; and
| | - Rotem Karmona
- Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel
| | - Boaz Tirosh
- The Institute for Drug Research, The School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem 91120, Israel
| | - Steffen Jung
- Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel;
| | - Ami Navon
- Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel;
| |
Collapse
|
4
|
Li Z, Zhang N, Ma L, Zhang L, Meng G, Xia C. The Mechanism of β2m Molecule-Induced Changes in the Peptide Presentation Profile in a Bony Fish. iScience 2020; 23:101119. [PMID: 32438322 PMCID: PMC7240133 DOI: 10.1016/j.isci.2020.101119] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2020] [Revised: 03/14/2020] [Accepted: 04/28/2020] [Indexed: 01/08/2023] Open
Abstract
Contemporary antigen presentation knowledge is based on the existence of a single β2m locus, and a classical MHC class I forms a complex with a peptide (i.e., pMHC-I) to trigger CTL immunity. However, two β2m loci have been found in diploid bony fish; the function of the two β2m molecules is unclear. Here, we determined the variant peptide profiles originating from different products of the β2m loci binding to the same MHC-I molecule and further solved the crystal structures of the two pMHC-I molecules (i.e., pCtid-UAA-β2m-2 and pCtid-UAA-β2m-1-II). Of note, in pCtid-UAA-β2m-2, a unique hydrogen bond network formed in the bottom of the peptide-binding groove (PBG) led to α2-helix drift, ultimately leading to structural changes in the PBG. The mechanism of the change in peptide presentation profiles by β2m molecules is illustrated. The results are also of great significance for antivirus and antitumor functions in cold-blooded vertebrates and even humans.
Collapse
Affiliation(s)
- Zibin Li
- Department of Microbiology and Immunology, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China
| | - Nianzhi Zhang
- Department of Microbiology and Immunology, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China
| | - Lizhen Ma
- Department of Microbiology and Immunology, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China
| | - Lijie Zhang
- Department of Microbiology and Immunology, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China
| | - Geng Meng
- Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Veterinary Medicine, China Agricultural University, Beijing, 100094, China
| | - Chun Xia
- Department of Microbiology and Immunology, College of Veterinary Medicine, China Agricultural University, Beijing, 100193, China.
| |
Collapse
|
5
|
Zhang L, Lin D, Yu S, Bai J, Jiang W, Su W, Huang Y, Yang S, Wu J. Polymorphism of duck MHC class molecules. Immunogenetics 2018; 71:49-59. [PMID: 30187087 DOI: 10.1007/s00251-018-1076-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2018] [Accepted: 08/10/2018] [Indexed: 01/09/2023]
Abstract
Major histocompatibility complex class I (MHC I) molecules are critically involved in defense against pathogens, and their high polymorphism is advantageous to a range of immune responses, especially in duck displaying biased expression of one MHC I gene. Here, we examined MHC I polymorphism in two duck (Anas platyrhynchos) breeds from China: Shaoxing (SX) and Jinding (JD). Twenty-seven unique UAA alleles identified from the MHC I genes of these breeds were analyzed concerning amino acid composition, homology, and phylogenetic relationships. Based on amino acid sequence homology, allelic groups of Anas platyrhynchos MHC I (Anpl-MHC I) were established and their distribution was analyzed. Then, highly variable sites (HVSs) in peptide-binding domains (PBD) were estimated and located in the three-dimensional structure of Anpl-MHC I. The UAA alleles identified showed high polymorphism, based on full-length sequence homology. By adding the alleles found here to known Anpl-MHC I genes from domestic ducks, they could be divided into 17 groups and four novel groups were revealed for SX and JD ducks. The UAA alleles of the two breeds were not divergent from the MHC I of other duck breeds, and HVSs were mostly located in the peptide-binding groove (PBG), suggesting that they might determine peptide-binding characteristics and subsequently influence peptide presentation and recognition. The results from the present study enrich Anpl-MHC I polymorphism data and clarify the distribution of alleles with different peptide-binding specificities, which might also accelerate effective vaccine development and help control various infections in ducks.
Collapse
Affiliation(s)
- Lin Zhang
- Shandong Key Laboratory of Disease Control and Breeding, Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Science, No. 8, Sangyuan Road, Jinan, Shandong, China.
| | - Dongmei Lin
- College of Life Sciences and Food Engineering, Hebei University of Engineering, 199, Guangming South Street, Handan, Hebei, China
| | - Sen Yu
- Shandong Key Laboratory of Disease Control and Breeding, Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Science, No. 8, Sangyuan Road, Jinan, Shandong, China
| | - Junping Bai
- Shandong Key Laboratory of Disease Control and Breeding, Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Science, No. 8, Sangyuan Road, Jinan, Shandong, China
- College of Life Sciences and Food Engineering, Hebei University of Engineering, 199, Guangming South Street, Handan, Hebei, China
| | - Wanchun Jiang
- College of Life Sciences and Food Engineering, Hebei University of Engineering, 199, Guangming South Street, Handan, Hebei, China
| | - Wenzheng Su
- Shandong Key Laboratory of Disease Control and Breeding, Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Science, No. 8, Sangyuan Road, Jinan, Shandong, China
| | - Yanyan Huang
- Shandong Key Laboratory of Disease Control and Breeding, Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Science, No. 8, Sangyuan Road, Jinan, Shandong, China
| | - Shaohua Yang
- Shandong Key Laboratory of Disease Control and Breeding, Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Science, No. 8, Sangyuan Road, Jinan, Shandong, China
| | - Jiaqiang Wu
- Shandong Key Laboratory of Disease Control and Breeding, Institute of Animal Science and Veterinary Medicine, Shandong Academy of Agricultural Science, No. 8, Sangyuan Road, Jinan, Shandong, China.
| |
Collapse
|
6
|
Shin JM, Song SH, Vijayakameswara Rao N, Lee ES, Ko H, Park JH. A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy. Biomater Res 2018; 22:21. [PMID: 30128166 PMCID: PMC6092827 DOI: 10.1186/s40824-018-0131-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Accepted: 07/30/2018] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Antigen-specific cytotoxic T lymphocytes (CTLs), which eliminate target cells bearing antigenic peptides presented by surface major histocompatibility complex (MHC) class I molecules, play a key role in cancer immunotherapy. However, the majority of tumors are not immunologically rejected since they express self-antigens which are not recognized by CTLs as foreign. To foreignize these tumors for CTL-mediated immunological rejection, it is essential to develop carriers that can effectively deliver foreign antigens to cancer cells. METHODS A polymeric conjugate, composed of a carboxymethyl dextran (CMD) as the backbone and ovalbumin (OVA) as a model foreign antigen, was prepared to investigate its potential as the antigen carrier for cancer immunotherapy. RESULTS An in vitro cellular uptake study showed that the conjugate was successfully taken up by TC-1 cervical cancer cells. When CMD-OVA was systemically administered to tumor-bearing mice, the strong fluorescence signal was observed at the tumor site over the whole period of time period, suggesting high tumor targetability of the conjugate. Compared to free OVA, CMD-OVA induced significantly higher antigen presentation at the tumor site. CONCLUSIONS The CMD-OVA conjugate can effectively deliver the antigen to the tumor site, implying its high potential as the antigen carrier for cancer immunotherapy.
Collapse
Affiliation(s)
- Jung Min Shin
- School of Chemical Engineering, Sungkyunkwan University, Suwon, 16419 Republic of Korea
| | - Seok Ho Song
- School of Chemical Engineering, Sungkyunkwan University, Suwon, 16419 Republic of Korea
| | | | - Eun Sook Lee
- Department of Health Science and Technology, SAIHST, Sungkyunkwan University, Suwon, 16419 Republic of Korea
| | - Hyewon Ko
- Department of Health Science and Technology, SAIHST, Sungkyunkwan University, Suwon, 16419 Republic of Korea
| | - Jae Hyung Park
- School of Chemical Engineering, Sungkyunkwan University, Suwon, 16419 Republic of Korea
- Department of Health Science and Technology, SAIHST, Sungkyunkwan University, Suwon, 16419 Republic of Korea
- School of Chemical Engineering, Sungkyunkwan University, Suwon, 440-746 Republic of Korea
| |
Collapse
|
7
|
Shin JM, Oh SJ, Kwon S, Deepagan VG, Lee M, Song SH, Lee HJ, Kim S, Song KH, Kim TW, Park JH. A PEGylated hyaluronic acid conjugate for targeted cancer immunotherapy. J Control Release 2017; 267:181-190. [PMID: 28844759 DOI: 10.1016/j.jconrel.2017.08.032] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Revised: 08/14/2017] [Accepted: 08/23/2017] [Indexed: 12/22/2022]
Abstract
The cell-free approach to foreignizing tumor cells with non-self antigens has received increasing attention as a method to induce cytotoxic T lymphocyte (CTL)-mediated immunological rejection of tumors, because the clinical translation of the conventional CTL-based cancer immunotherapies has been limited by a complicated manufacturing process and autotransplantation. In this study, we prepared matrix metalloproteinase 9 (MMP9)-responsive polymeric conjugates consisting of PEGylated hyaluronic acid (HA) as the targeting moiety and ovalbumin (OVA) as the model foreign antigen. The MMP9-cleavable linker was introduced between PEG and the HA backbone to facilitate the detachment of the PEG corona from the conjugate at the tumor site. From the in vitro cellular uptake study, it was revealed that the conjugate was effectively taken up by the CD44-expressing TC-1 cancer cells in the presence of MMP9 via receptor-mediated endocytosis. When the conjugate was systemically administered into the tumor-bearing mice with endogenous OVA-specific CTLs, the tumor growth was markedly inhibited, which was attributed to the significant antigen presentation on the tumor cells. Overall, the MMP9-responsive conjugates bearing foreign antigens might have the potential as an alternative to CTL-based cancer immunotherapeutics.
Collapse
Affiliation(s)
- Jung Min Shin
- School of Chemical Engineering, College of Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Se Jin Oh
- Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Biochemistry and Molecular Biology, College of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Biomedical Science, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Seunglee Kwon
- School of Chemical Engineering, College of Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - V G Deepagan
- School of Chemical Engineering, College of Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Minchang Lee
- School of Chemical Engineering, College of Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Seok Ho Song
- School of Chemical Engineering, College of Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
| | - Hyo-Jung Lee
- Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Biochemistry and Molecular Biology, College of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Biomedical Science, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Suyeon Kim
- Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Biochemistry and Molecular Biology, College of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Biomedical Science, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Kwon-Ho Song
- Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Biochemistry and Molecular Biology, College of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Biomedical Science, College of Medicine, Korea University, Seoul 02841, Republic of Korea
| | - Tae Woo Kim
- Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Biochemistry and Molecular Biology, College of Medicine, Korea University, Seoul 02841, Republic of Korea; Department of Biomedical Science, College of Medicine, Korea University, Seoul 02841, Republic of Korea; Translational Research Institute for Incurable Diseases, College of Medicine, Korea University, Seoul 02841, Republic of Korea.
| | - Jae Hyung Park
- School of Chemical Engineering, College of Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea.
| |
Collapse
|
8
|
Ghosh MK, Muller HK, Walker AM. Lactation-Based Maternal Educational Immunity Crosses MHC Class I Barriers and Can Impart Th1 Immunity to Th2-Biased Recipients. THE JOURNAL OF IMMUNOLOGY 2017; 199:1729-1736. [PMID: 28747348 DOI: 10.4049/jimmunol.1601375] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Accepted: 06/23/2017] [Indexed: 11/19/2022]
Abstract
We have previously demonstrated lactational transfer of T cell-based immunity from dam to foster pup. In the short term, a significant part of transferred immunity is passive cellular immunity. However, as time progresses, this is replaced by what we have described as maternal educational immunity such that by young adulthood, all immune cells responding to a foster dam immunogen are the product of the foster pup's thymus. To reduce confounding factors, this original demonstration used congenic/syngeneic dam and foster pup pairs. In this study, we investigated lactational transfer of immunity to Mycobacterium tuberculosis in MHC class I-mismatched animals, as well as from Th1-biased dams to Th2-biased foster pups. Using immunized C57BL/6J dams, lactational transfer to nonimmunized BALB/cJ foster pups resulted in much greater immunity than direct immunization in 5-wk-old pups (ex vivo assay of pup splenocytes). At this age, 82% of immunogen-responding cells in the pup spleen were produced through maternal educational immunity. FVB/NJ nonimmunized foster recipients had a greater number of maternal cells in the spleen and thymus but a much larger percentage was Foxp3+, resulting in equivalent immunity to direct immunization. Depletion of maternal Foxp3+ cells from pup splenocytes illustrated a substantial role for lactationally transferred dam regulatory T cells in suppression of the ex vivo response in FVB/NJ, but not BALB/cJ, recipients. We conclude that lactational transfer of immunity can cross MHC class I barriers and that Th1 immunity can be imparted to Th2-biased offspring; in some instances, it can be greater than that achieved by direct immunization.
Collapse
Affiliation(s)
- Mrinal K Ghosh
- Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA 92521; and
| | - H Konrad Muller
- School of Medicine, University of Tasmania, Hobart 7000, Tasmania, Australia
| | - Ameae M Walker
- Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA 92521; and
| |
Collapse
|
9
|
Structural Definition of Duck Major Histocompatibility Complex Class I Molecules That Might Explain Efficient Cytotoxic T Lymphocyte Immunity to Influenza A Virus. J Virol 2017; 91:JVI.02511-16. [PMID: 28490583 PMCID: PMC5487541 DOI: 10.1128/jvi.02511-16] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2017] [Accepted: 04/26/2017] [Indexed: 01/16/2023] Open
Abstract
A single dominantly expressed allele of major histocompatibility complex class I (MHC I) may be responsible for the duck's high tolerance to highly pathogenic influenza A virus (HP-IAV) compared to the chicken's lower tolerance. In this study, the crystal structures of duck MHC I (Anpl-UAA*01) and duck β2-microglobulin (β2m) with two peptides from the H5N1 strains were determined. Two remarkable features were found to distinguish the Anpl-UAA*01 complex from other known MHC I structures. A disulfide bond formed by Cys95 and Cys112 and connecting the β5 and β6 sheets at the bottom of peptide binding groove (PBG) in Anpl-UAA*01 complex, which can enhance IAV peptide binding, was identified. Moreover, the interface area between duck MHC I and β2m was found to be larger than in other species. In addition, the two IAV peptides that display distinctive conformations in the PBG, B, and F pockets act as the primary anchor sites. Thirty-one IAV peptides were used to verify the peptide binding motif of Anpl-UAA*01, and the results confirmed that the peptide binding motif is similar to that of HLA-A*0201. Based on this motif, approximately 600 peptides from the IAV strains were partially verified as the candidate epitope peptides for Anpl-UAA*01, which is a far greater number than those for chicken BF2*2101 and BF2*0401 molecules. Extensive IAV peptide binding should allow for ducks with this Anpl-UAA*01 haplotype to resist IAV infection. IMPORTANCE Ducks are natural reservoirs of influenza A virus (IAV) and are more resistant to the IAV than chickens. Both ducks and chickens express only one dominant MHC I locus providing resistance to the virus. To investigate how MHC I provides IAV resistance, crystal structures of the dominantly expressed duck MHC class I (pAnpl-UAA*01) with two IAV peptides were determined. A disulfide bond was identified in the peptide binding groove that can facilitate Anpl-UAA*01 binding to IAV peptides. Anpl-UAA*01 has a much wider recognition spectrum of IAV epitope peptides than do chickens. The IAV peptides bound by Anpl-UAA*01 display distinctive conformations that can help induce an extensive cytotoxic T lymphocyte (CTL) response. In addition, the interface area between the duck MHC I and β2m is larger than in other species. These results indicate that HP-IAV resistance in ducks is due to extensive CTL responses induced by MHC I.
Collapse
|
10
|
Zoccola E, Delamare-Deboutteville J, Barnes AC. Identification of Barramundi (Lates calcarifer) DC-SCRIPT, a Specific Molecular Marker for Dendritic Cells in Fish. PLoS One 2015; 10:e0132687. [PMID: 26173015 PMCID: PMC4501824 DOI: 10.1371/journal.pone.0132687] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 06/18/2015] [Indexed: 11/18/2022] Open
Abstract
Antigen presentation is a critical step bridging innate immune recognition and specific immune memory. In mammals, the process is orchestrated by dendritic cells (DCs) in the lymphatic system, which initiate clonal proliferation of antigen-specific lymphocytes. However, fish lack a classical lymphatic system and there are currently no cellular markers for DCs in fish, thus antigen-presentation in fish is poorly understood. Recently, antigen-presenting cells similar in structure and function to mammalian DCs were identified in various fish, including rainbow trout (Oncorhynchus mykiss) and zebrafish (Danio rerio). The present study aimed to identify a potential molecular marker for DCs in fish and therefore targeted DC-SCRIPT, a well-conserved zinc finger protein that is preferentially expressed in all sub-types of human DCs. Putative dendritic cells were obtained in culture by maturation of spleen and pronephros-derived monocytes. DC-SCRIPT was identified in barramundi by homology using RACE PCR and genome walking. Specific expression of DC-SCRIPT was detected in barramundi cells by Stellaris mRNA FISH, in combination with MHCII expression when exposed to bacterial derived peptidoglycan, suggesting the presence of DCs in L. calcarifer. Moreover, morphological identification was achieved by light microscopy of cytospins prepared from these cultures. The cultured cells were morphologically similar to mammalian and trout DCs. Migration assays determined that these cells have the ability to move towards pathogens and pathogen associated molecular patterns, with a preference for peptidoglycans over lipopolysaccharides. The cells were also strongly phagocytic, engulfing bacteria and rapidly breaking them down. Barramundi DCs induced significant proliferation of responder populations of T-lymphocytes, supporting their role as antigen presenting cells. DC-SCRIPT expression in head kidney was higher 6 and 24 h following intraperitoneal challenge with peptidoglycan and lipopolysaccharide and declined after 3 days relative to PBS-injected controls. Relative expression was also lower in the spleen at 3 days post challenge but increased again at 7 days. As DC-SCRIPT is a constitutively expressed nuclear receptor, independent of immune activation, this may indicate initial migration of immature DCs from head kidney and spleen to the injection site, followed by return to the spleen for maturation and antigen presentation. DC-SCRIPT may be a valuable tool in the investigation of antigen presentation in fish and facilitate optimisation of vaccines and adjuvants for aquaculture.
Collapse
Affiliation(s)
- Emmanuelle Zoccola
- The University of Queensland, School of Biological Sciences and Centre for Marine Science, Brisbane, Queensland, 4072, Australia
| | - Jérôme Delamare-Deboutteville
- The University of Queensland, School of Biological Sciences and Centre for Marine Science, Brisbane, Queensland, 4072, Australia
| | - Andrew C. Barnes
- The University of Queensland, School of Biological Sciences and Centre for Marine Science, Brisbane, Queensland, 4072, Australia
- * E-mail:
| |
Collapse
|
11
|
Pavlenko M, Leder C, Pisa P. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. Expert Rev Vaccines 2014; 4:315-27. [PMID: 16026247 DOI: 10.1586/14760584.4.3.315] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In recent years, a number of tumor vaccination strategies have been developed. Most of these rely on the identification of tumor antigens that can be recognized by the immune system. DNA vaccination represents one such approach for the induction of both humoral and cellular immune responses against tumor antigens. Studies in animal models have demonstrated the feasibility of utilizing DNA vaccination to elicit protective antitumor immune responses. However, most tumor antigens expressed by cancer cells in humans are weakly immunogenic, and therefore require the development of strategies to potentiate DNA vaccine efficacy in the clinical setting. This review focuses on recent advances in understanding of the immunology of DNA vaccines, as well as strategies used to increase DNA vaccine potency with respect to cytotoxic T-lymphocyte activity.
Collapse
Affiliation(s)
- Maxim Pavlenko
- Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, Stockholm S-171 76, Sweden.
| | | | | |
Collapse
|
12
|
Virosome presents multimodel cancer therapy without viral replication. BIOMED RESEARCH INTERNATIONAL 2013; 2013:764706. [PMID: 24369016 PMCID: PMC3866828 DOI: 10.1155/2013/764706] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/08/2013] [Accepted: 10/31/2013] [Indexed: 12/11/2022]
Abstract
A virosome is an artificial envelope that includes viral surface proteins and lacks the ability to produce progeny virus. Virosomes are able to introduce an encapsulated macromolecule into the cytoplasm of cells using their viral envelope fusion ability. Moreover, virus-derived factors have an adjuvant effect for immune stimulation. Therefore, many virosomes have been utilized as drug delivery vectors and adjuvants for cancer therapy. This paper introduces the application of virosomes for cancer treatment. In Particular, we focus on virosomes derived from the influenza and Sendai viruses which have been widely used for cancer therapy. Influenza virosomes have been mainly applied as drug delivery vectors and adjuvants. By contrast, the Sendai virosomes have been mainly applied as anticancer immune activators and apoptosis inducers.
Collapse
|
13
|
Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K. Cell Mol Immunol 2013; 10:275-82. [PMID: 23524651 DOI: 10.1038/cmi.2012.74] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Tumor-associated antigen 90K is implicated in cell-cell and cell-extracellular matrix adhesion through its interaction with galectin-3 and integrin-β1 and is highly expressed in malignant tissues, making it a novel target for the development of new immunotherapies. We investigated a potential immunotherapy treatment for colon cancer using 90K-specific cytotoxic T lymphocytes induced by autologous dendritic cells and pulsed with 90K peptides. We selected three peptides (90K351, 90K5 and 90K523) that bind to HLA-A*0201 molecules on the basis of their binding affinity, as determined by a peptide-T2 binding assay. Dendritic cells pulsed with 90K peptides resulted in the efficient generation of mature dendritic cells and exhibited enhanced T-cell stimulation and polarization of naive T cells toward Th1. Dendritic cells pulsed with 90K peptides generated potent cytotoxic T-lymphocytes that lysed T2 cells loaded with each 90K peptide, and 90K(+)/HLA-A2(+) colon cancer cell lines, including HCT116 and SW480, in a dose-dependent and HLA-A*0201-restricted manner. No killing was observed in 90K(+)/HLA-A2(-) DLD1 or 90K(-)/HLA-A2(-) K562 cells. Therefore, we believe that cytotoxic T-lymphocytes stimulated by 90K peptide-pulsed dendritic cells naturally recognize the 90K peptide presented by colon cancer cells in the context of HLA-A2, and kill 90K-positive tumor cells. Dendritic cells pulsed with 90K peptides led to the induction of granzyme B and perforin positive CD8(+) T cells against HCT116 and SW480 cells, but not DLD1 cells. In conclusion, 90K-specific cytotoxic T lymphocytes, generated by stimulating T cells with 90K peptide-pulsed dendritic cells, could be useful effector cells for the immunotherapy treatment of colon cancer.
Collapse
|
14
|
A polymeric protein induces specific cytotoxicity in a TLR4 dependent manner in the absence of adjuvants. PLoS One 2012; 7:e45705. [PMID: 23029192 PMCID: PMC3454435 DOI: 10.1371/journal.pone.0045705] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2012] [Accepted: 08/22/2012] [Indexed: 11/19/2022] Open
Abstract
Lumazine synthase from Brucella spp. (BLS) is a highly immunogenic decameric protein. It is possible to insert foreign peptides or proteins at its ten-amino acid termini. These chimeras elicit systemic and oral immunity without adjuvants, which are commonly needed in the formulation of subunit-based vaccines. Here, we show that BLS induces the cross presentation of a covalently attached peptide OVA257–264 and a specific cytotoxic response to this peptide in the absence of adjuvants. Unlike other subunit-based vaccines, this chimera induces rapid activation of CTLs and a specific cytotoxic response, making this polymeric protein an ideal antigen carrier for vaccine development. Adoptive transfer of transgenic OT-I T cells revealed efficient cross presentation of BLS-OVA257–264in vivo. BLS-OVA257–264 immunization induced the proliferation of OVA257–264-specific CD8+ lymphocytes and also increased the percentage of OVA257–264-specific CD8+ cells expressing the early activation marker CD69; after 5 days, the percentage of OVA257–264-specific CD8+ cells expressing high levels of CD44 increased. This cell subpopulation showed decreased expression of IL-7Rα, indicating that BLS-OVA257–264 induced the generation of CD8+ effector cells. BLS-OVA257–264 was cross presented in vitro independently of the presence of a functional TLR4 in the DCs. Finally, we show that immunization of wild type mice with the chimera BLS-OVA257–264 without adjuvants induced a strong OVA257–264-specific effector cytotoxic response. This cytotoxicity is dependent on TLR4 as is not induced in mice lacking a functional receptor. These data show that TLR4 signaling is necesary for the induction of a cytotoxic response but not for antigen cross presentation.
Collapse
|
15
|
Abstract
Two striking facts surround the practice of vaccination: It is the sole medical approach to have fully annihilated a disease, yet the development of most effective vaccines took place without considering the intricate cellular processes they wish to effectuate. While extremely potent vaccines have been developed that can protect practically a lifetime after a single dose, numerous other vaccines have utterly failed or provide only marginal protection. Here, we aim to illustrate why this difference in efficacy exists, and underline why specific cytotoxic T cell-inducing vaccines could combat persistent major diseases. Moreover, we discuss how the combinatorial use of nucleic acid adjuvants in vaccines could aid the development of the latter and move vaccine design from the empirical stage into an era of "educated design."
Collapse
|
16
|
Facciponte JG, MacDonald IJ, Wang XY, Kim H, Manjili MH, Subjeck JR. Heat Shock Proteins and Scavenger Receptors: Role in Adaptive Immune Responses. Immunol Invest 2009; 34:325-42. [PMID: 16136784 DOI: 10.1081/imm-200064505] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Tumor-derived heat shock proteins have shown promise as anti-cancer vaccines in clinical trials. Heat shock proteins (HSPs) can generate potent anti-tumor immunity and elicit antigen-specific CD8+ T cell responses in murine studies. Antigen presenting cells (APC), such as macrophages and dendritic cells (DCs), can elicit antigen-specific CD8+ T cell responses mediated by HSPs. CD91 was the first identified endocytic scavenger receptor for HSPs on APC that can facilitate the process of cross-presentation. Other scavenger receptors may also play a similar role in this process. The present review critically evaluates the identified HSP endocytic receptors on APCs that may generate adaptive immune responses. A better understanding of this interaction between HSPs and APCs may further unravel mechanisms of immunoadjuvant function of HSPs.
Collapse
Affiliation(s)
- John G Facciponte
- Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York, USA
| | | | | | | | | | | |
Collapse
|
17
|
Keller SA, von Allmen CE, Hinton HJ, Bauer M, Muntwiler S, Dietmeier K, Saudan P, Bachmann MF. Follicular and Marginal Zone B Cells Fail to Cross-Present MHC Class I-Restricted Epitopes Derived from Viral Particles. THE JOURNAL OF IMMUNOLOGY 2009; 182:6261-6. [DOI: 10.4049/jimmunol.0804035] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
18
|
Kaur M, Rai A, Bhatnagar R. Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge. Vaccine 2009; 27:2128-37. [PMID: 19356616 PMCID: PMC7115670 DOI: 10.1016/j.vaccine.2009.01.128] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2008] [Revised: 01/24/2009] [Accepted: 01/29/2009] [Indexed: 11/23/2022]
Abstract
Rabies is progressive fatal encephalitis. WHO estimates 55,000 rabies deaths and more than 10 million PEP every year world-wide. A variety of cell-culture derived vaccines are available for prophylaxis against rabies. However, their high cost restricts their usage in developing countries, where such cases are most often encountered. This is driving the quest for newer vaccine formulations; DNA vaccines being most promising amongst them. Here, we explored strategies of antigen trafficking to various cellular compartments aiming at improving both humoral and cellular immunity. These strategies include use of signal sequences namely Tissue Plasminogen Activator (TPA), Ubiquitin (UQ) and Lysosomal-Associated Membrane Protein-1 (LAMP-1). TPA, LAMP-1 and their combination were aimed at enhancing the CD4(+) T cell and antibody response. In contrast, the UQ tag was utilized for enhancing CD8(+) response. The potency of modified DNA vaccines assessed by total antibody response, antibody isotypes, cytokine profile, neutralizing antibody titer and protection conferred against in vivo challenge; was enhanced in comparison to native unmodified vaccine, but the response elicited did not pertain to the type of target sequence and the directed arm of immunity. Interestingly, the DNA vaccines that had been designed to generate different type of immune responses yielded in effect similar response. In conclusion, our data indicate that the directing target sequence is not the exclusive deciding factor for type and extent of immune response elicited and emphasizes on the antigen dependence of immune enhancement strategies.
Collapse
Key Words
- ab, antibody
- ig, immunoglobulin
- elisa, enzyme linked immunosorbent assay
- gp, glycoprotein
- lamp-1, lysosomal-associated membrane protein-1
- mhc, major histocompatibility complex
- mq, milli quartz water
- pmsf, phenyl methyl sulphonyl fluoride
- ripa, radioimmunoprecipitation assay buffer
- rffit, rapid fluorescence focus inhibition test
- tm, transmembrane
- tpa, tissue plasminogen activator
- tris, tris(hydroxymethyl) aminomethane
- uq, ubiquitin
- targeting sequence
- rabies virus-neutralizing antibody (rvna)
- survival
Collapse
Affiliation(s)
- Manpreet Kaur
- Laboratory Of Molecular Biology And Genetic Engineering, School Of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, Delhi, India
| | | | | |
Collapse
|
19
|
Cheong WS, Reiseger J, Turner SJ, Boyd R, Netter HJ. Chimeric virus-like particles for the delivery of an inserted conserved influenza A-specific CTL epitope. Antiviral Res 2009; 81:113-22. [DOI: 10.1016/j.antiviral.2008.10.003] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2008] [Revised: 10/08/2008] [Accepted: 10/10/2008] [Indexed: 11/29/2022]
|
20
|
Arcuri M, Cappelletti M, Zampaglione I, Aurisicchio L, Nicosia A, Ciliberto G, Fattori E. Synergistic effect of gene-electro transfer and adjuvant cytokines in increasing the potency of hepatitis C virus genetic vaccination. J Gene Med 2008; 10:1048-54. [DOI: 10.1002/jgm.1217] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
21
|
Tiwari N, Garbi N, Reinheckel T, Moldenhauer G, Hämmerling GJ, Momburg F. A transporter associated with antigen-processing independent vacuolar pathway for the MHC class I-mediated presentation of endogenous transmembrane proteins. THE JOURNAL OF IMMUNOLOGY 2007; 178:7932-42. [PMID: 17548631 DOI: 10.4049/jimmunol.178.12.7932] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
MHC class I molecules present peptides derived from the ectodomains of endogenous transmembrane proteins; however, the processing of these Ags is incompletely understood. As model transmembrane Ags we investigated the processing of MHC-I-derived fusion proteins containing the N-terminally extended K(b)-restricted OVA epitope SIINFEKL in the extracytoplasmic domain. In TAP-deficient, nonprofessional APCs, the epitope was cleaved out of various sequence contexts and presented to T cells. Ag presentation was inhibited by acidophilic amines and inhibitors of the vacuolar proton pump, indicating processing in endosomes. Endosomal aspartic-type cathepsins, and to some extent also the trans-Golgi network protease furin, were involved in processing. Clathrin-dependent and independent internalization from the cell surface targeted MHC-I fusion proteins to early and late endosomes, where SIINFEKL/K(b) complexes were detected by immunofluorescence microscopy. Targeting of MHC-I fusion proteins to processing compartments was independent of sequence motifs in the cytoplasmic tail. Not only TAP-deficient cells, but also TAP-competent APCs used the vacuolar pathway for processing of MHC-I fusion proteins. Thus, endosomal processing of internalized endogenous transmembrane proteins represents a novel alternate pathway for the generation of MHC-I-binding peptides.
Collapse
Affiliation(s)
- Neeraj Tiwari
- Department of Molecular Immunology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
| | | | | | | | | | | |
Collapse
|
22
|
Pavlenko M, Leder C, Moreno S, Levitsky V, Pisa P. Priming of CD8+ T-cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice. Vaccine 2007; 25:6341-7. [PMID: 17628235 DOI: 10.1016/j.vaccine.2007.06.016] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2007] [Revised: 06/11/2007] [Accepted: 06/11/2007] [Indexed: 11/18/2022]
Abstract
The plasmid DNA vaccine not only provides expression of the antigen in vivo, but also activates cells of the innate immune system via unmethylated CpG-containing DNA sequences that are recognized by Toll like receptor 9 (TLR9). The requirement of such immunostimulatory activity for induction of CD8+ T-cell responses after DNA immunization is still controversial. In the present study we assessed induction of CD8+ T-cell responses against an immunodominant H-2D(b)-restricted epitope of human prostate-specific antigen in C57Bl/6 (wild-type), TLR9- and MyD88-deficient mice. A single DNA immunization resulted in efficient priming of CD8+ T responses in wild-type mice but not in TLR9- or MyD88-deficient mice. However, priming of CD8+ T cell responses was observed in TLR9-deficient but not in MyD88-deficient mice after multiple DNA immunizations. Moreover, induction of CD8+ T cell responses in TLR9-deficient mice was dependent on the presence of endotoxin contamination in plasmid DNA preparations. Collectively, these results demonstrate that TLR9-dependent immunostimulatory activity of plasmid DNA is essential for priming of CD8+ T-cell responses and that other bacterial compounds present in plasmid DNA preparations and acting via MyD88-dependent pathway could provide alternative signals necessary for priming of CD8+ T cells.
Collapse
Affiliation(s)
- Maxim Pavlenko
- Department of Oncology and Pathology, Cancer Center Karolinska, Immune and Gene Therapy Laboratory, Karolinska Institute, Stockholm, Sweden
| | | | | | | | | |
Collapse
|
23
|
Besold K, Frankenberg N, Pepperl-Klindworth S, Kuball J, Theobald M, Hahn G, Plachter B. Processing and MHC class I presentation of human cytomegalovirus pp65-derived peptides persist despite gpUS2–11-mediated immune evasion. J Gen Virol 2007; 88:1429-1439. [PMID: 17412970 DOI: 10.1099/vir.0.82686-0] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Immune control of human cytomegalovirus (HCMV) infection can be mediated by CD8+cytolytic T lymphocytes (CTL). Adoptive transfer of antiviral CTL confers protection against HCMV reactivation and disease. The tegument protein pp65 and the immediate-early 1 protein (IE1) are recognized to be major CTL targets, even though during productive infection the viral immunoevasion proteins gpUS2–11 act to suppress major histocompatibility complex (MHC) class I-restricted antigen presentation. Thus it was not clear how infected cells could be labelled with antigenic peptides in the face of immunoevasion. We show here that the immunodominant peptide pp65NLVwas presented by MHC class I in cells infected with a gpUS2–11-competent virus. Presentation of pp65NLVwas still detectable at 96 h post-infection, although at low levels. Partial suppression of pp65NLVpresentation was dependent on the ability of the infecting strain to express gpUS2–11. MHC class I-restricted antigen presentation in HCMV-infected cells (encoding gpUS2–11) exhibited specificity for pp65-derived peptides, as infected fibroblasts did not present the IE1-derived nonapeptide IE1TMY. Remarkably, infected cells could restore pp65NLVpeptide presentation after acid removal of MHC class I despite gpUS2–11 expression. This recovery was shown to be dependent on proteasome functionality. In contrast to IE1, pp65 peptides are loaded on MHC class I molecules to be transported to the cell surface at early and late times after infection in the face of gpUS2–11-mediated immunoevasion. pp65 is therefore the first example of an HCMV protein only incompletely subjected to gpUS2–11-mediated immunoevasion.
Collapse
Affiliation(s)
- Katrin Besold
- Institute of Virology, Johannes Gutenberg-Universität, Mainz, Germany
| | | | | | - Jürgen Kuball
- Department of Hematology and Oncology, Johannes Gutenberg-Universität, Mainz, Germany
| | - Matthias Theobald
- Department of Hematology and Oncology, Johannes Gutenberg-Universität, Mainz, Germany
| | - Gabriele Hahn
- Max von Pettenkofer Institut, Department of Virology, Ludwig-Maximilians-Universität München, Germany
| | - Bodo Plachter
- Institute of Virology, Johannes Gutenberg-Universität, Mainz, Germany
| |
Collapse
|
24
|
Li Q, Gao JQ, Qiu LY, Cui FD, Jin Y. Enhanced immune responses induced by vaccine using Sendai virosomes as carrier. Int J Pharm 2007; 329:117-21. [PMID: 17046184 DOI: 10.1016/j.ijpharm.2006.08.033] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2005] [Revised: 08/23/2006] [Accepted: 08/25/2006] [Indexed: 11/16/2022]
Abstract
Sendai virosomes can deliver encapsulated contents into the cytoplasm directly in a virus fusion-dependent manner. In this paper, Sendai virosomes-formulated melanoma vaccine was constructed and its anti-tumor effects were investigated. The melanoma vaccine was prepared by encapsulating mixture antigen into the Sendai virosomes. The antigen, mixture proteins were extracted from B(16) melanoma cells. The cytotoxic T lymphocyte (CTL) response level was evaluated by (51)Cr release method, and the change of CD4(+) and CD8(+) expression as well as the concentration of IgG in serum of immunized mice was measured. The results showed that Sendai virosomes-formulated melanoma vaccine can effectively elicit not only systemic immune response but also strong CTL response. Sendai virosomes can be used as an effective vector for use in anti-tumor vaccine therapy.
Collapse
Affiliation(s)
- Qiang Li
- College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310031, PR China
| | | | | | | | | |
Collapse
|
25
|
Gray RC, Kuchtey J, Harding CV. CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs. J Leukoc Biol 2007; 81:1075-85. [PMID: 17227820 DOI: 10.1189/jlb.1006606] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Deoxycytidyl-deoxyguanosine [(CpG)3] oligodeoxynucleotides (ODNs) signal through TLR9 to induce type-I IFN (IFN-alphabeta) and IFN-alphabeta-dependent MHC-I cross-presentation of exogenous antigens by dendritic cells (DCs). A puzzle was presented by our observation that three ODN classes, CpG-A, CpG-B, and CpG-C, had similar efficacy for induction of IFN-alphabeta-dependent MHC-I antigen cross-presentation by myeloid DCs despite greatly differing for induction of IFN-alphabeta (CpG-A>CpG-C>>CpG-B). All ODN classes similarly enhanced plasmacytoid DC (pDC) presentation of exogenous MHC-I-restricted peptide, although pDCs did not cross-process protein antigen. MHC-I and the transporter for antigen presentation were induced by all ODN classes or IFN-alpha. CpG-B ODNs were slightly more potent than CpG-A or CpG-C ODNs for induction of low levels of IFN-alphabeta but less efficacious at high concentrations than CpG-A or CpG-C ODNs. Low levels of IFN-alphabeta induced by CpG-B ODNs sufficed for full induction of MHC-I cross-presentation. Thus, CpG-B ODNs are slightly more potent but less efficacious than CpG-A and CpG-C ODNs for induction of IFN-alphabeta. High sensitivity to IFN-alphabeta allows CpG-B ODNs to be equally efficacious for induction of MHC-I cross-presentation. CpG-B ODNs may be effective for inducing therapeutic responses that require low levels of IFN-alphabeta and may avoid unnecessarily high induction of IFN-alphabeta.
Collapse
Affiliation(s)
- Reginald C Gray
- Department of Pathology, Center for AIDS Research, WRB 5534, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106-7288, USA
| | | | | |
Collapse
|
26
|
Abstract
Vaccination is one of the most efficient ways to eradicate some infectious diseases in humans and animals. The material traditionally used as vaccines is attenuated or inactivated pathogens. This approach is sometimes limited by the fact that the material for vaccination is not efficient, not available, or generating deleterious side effects. A possible theoretical alternative is the use of recombinant proteins from the pathogens. This implies that the proteins having the capacity to vaccinate have been identified and that they can be produced in sufficient quantity at a low cost. Genetically modified organisms harboring pathogen genes can fulfil these conditions. Microorganisms, animal cells as well as transgenic plants and animals can be the source of recombinant vaccines. Each of these systems that are all getting improved has advantages and limits. Adjuvants must generally be added to the recombinant proteins to enhance their vaccinating capacity. This implies that the proteins used to vaccinate have been purified to avoid any immunization against the contaminants. The efficiency of a recombinant vaccine is poorly predictable. Multiple proteins and various modes of administration must therefore be empirically evaluated on a case-by-case basis. The structure of the recombinant proteins, the composition of the adjuvants and the mode of administration of the vaccines have a strong and not fully predictable impact on the immune response as well as the protection level against pathogens. Recombinant proteins can theoretically also be used as carriers for epitopes from other pathogens. The increasing knowledge of pathogen genomes and the availability of efficient systems to prepare large amounts of recombinant proteins greatly facilitate the potential use of recombinant proteins as vaccines. The present review is a critical analysis of the state of the art in this field.
Collapse
Affiliation(s)
- Eric Soler
- Cell Biology Department, Erasmus MC, dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands.
| | | |
Collapse
|
27
|
Ragde H, Cavanagh WA, Tjoa BA. Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 2006; 172:2532-8. [PMID: 15538202 DOI: 10.1097/01.ju.0000144211.51111.e4] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
PURPOSE No effective treatment is currently available for metastatic prostate cancer. Dendritic cell (DC) based cancer vaccine research has emerged from the laboratories to human clinical trials. We describe progress in the development of DC based prostate cancer vaccine. MATERIALS AND METHODS The literature was reviewed for major contributions to a growing number of studies that demonstrate the potential of DC based immunotherapeutics for prostate cancer. Background topics relating to DC based immunotherapy theory and practice are also addressed. RESULTS DCs have been recognized as the most efficient antigen presenting cells that have the capacity to initiate naive T cell response in vitro and in vivo. During their differentiation and maturation pathways, dendritic cells can efficiently capture, process and present antigens for T cell activation. These characteristics make DC an attractive choice as the cellular adjuvant for cancer vaccines. Advances in DC generation, loading, and maturation methodologies have made it possible to generate clinical grade vaccines for various human trials. More than 100 DC vaccine trials, including 7 studies of patients with advanced prostate cancer have been reported to date. These vaccines were generally well tolerated with no significant adverse toxicity reported. Clinical responders have been identified in these studies. CONCLUSIONS The new prospects opened by DC based vaccines for prostate cancer are fascinating. When compared to conventional treatments, DC vaccinations have few side effects. Improvements in patient selection, vaccine delivery strategies, immune monitoring and vaccine manufacturing will be crucial in moving DC based prostate cancer vaccines closer to the clinics.
Collapse
Affiliation(s)
- Haakon Ragde
- Haakon Ragde Foundation for Advanced Cancer Studies, Seattle, Washington, USA.
| | | | | |
Collapse
|
28
|
Arruda LB, Sim D, Chikhlikar PR, Maciel M, Akasaki K, August JT, Marques ETA. Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2006; 177:2265-75. [PMID: 16887987 DOI: 10.4049/jimmunol.177.4.2265] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Ag processing is a critical step in defining the repertoire of epitope-specific immune responses. In the present study, HIV-1 p55Gag Ag was synthesized as a DNA plasmid with either lysosomal-associated membrane protein-1 (LAMP/gag) or human dendritic cell-LAMP (DC-LAMP/gag) and used to immunize mice. Analysis of the cellular trafficking of these two chimeras demonstrated that both molecules colocalized with MHC class II molecules but differed in their overall trafficking to endosomal/lysosomal compartments. Following DNA immunization, both chimeras elicited potent Gag-specific T and B cell immune responses in mice but differ markedly in their IL-4 and IgG1/IgG2a responses. The DC-LAMP chimera induced a stronger Th type 1 response. ELISPOT analysis of T cell responses to 122 individual peptides encompassing the entire p55gag sequence (15-aa peptides overlapping by 11 residues) showed that DNA immunization with native gag, LAMP/gag, or DC-LAMP/gag induced responses to identical immunodominant CD4+ and CD8+ peptides. However, LAMP/gag and DC-LAMP/gag plasmids also elicited significant responses to 23 additional cryptic epitopes that were not recognized after immunization with native gag DNA. The three plasmids induced T cell responses to a total of 39 distinct peptide sequences, 13 of which were induced by all three DNA constructs. Individually, DC-LAMP/gag elicited the most diverse response, with a specific T cell response against 35 peptides. In addition, immunization with LAMP/gag and DC-LAMP/gag chimeras also promoted Ab secretion to an increased number of epitopes. These data indicate that LAMP-1 and DC-LAMP Ag chimeras follow different trafficking pathways, induce distinct modulatory immune responses, and are able to present cryptic epitopes.
Collapse
Affiliation(s)
- Luciana B Arruda
- Department of Pharmacology and Molecular Sciences, The Johns Hopkins School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA
| | | | | | | | | | | | | |
Collapse
|
29
|
Yan J, Ling S, Liu H, Zhang H, Song X, Xiu B, Chen K, Wang G, Zhu C. Induction of strong cytotoxic T-lymphocyte responses to hepatitis C virus with recombinant poly-epitope in BALB/c mice. Viral Immunol 2006; 19:64-73. [PMID: 16553551 DOI: 10.1089/vim.2006.19.64] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Affiliation(s)
- J Yan
- Department of Vaccine Engineering, Beijing Institute of Basic Medical Sciences, Beijing, China
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Schuurhuis DH, van Montfoort N, Ioan-Facsinay A, Jiawan R, Camps M, Nouta J, Melief CJM, Verbeek JS, Ossendorp F. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. THE JOURNAL OF IMMUNOLOGY 2006; 176:4573-80. [PMID: 16585547 DOI: 10.4049/jimmunol.176.8.4573] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Dendritic cells (DCs) play an important role in the induction of T cell responses. Fc gammaRs, expressed on DCs, facilitate the uptake of complexed Ag, resulting in efficient MHC class I and MHC class II Ag presentation and DC maturation. In the present study, we show that prophylactic immunization with DCs loaded with Ag-IgG immune complexes (ICs) leads to efficient induction of tumor protection in mice. Therapeutic vaccinations strongly delay tumor growth or even prevent tumors from growing out. By depleting CD4+ and CD8+ cell populations before tumor challenge, we identify CD8+ cells as the main effector cells involved in tumor eradication. Importantly, we show that DCs that are preloaded in vitro with ICs are at least 1000-fold more potent than ICs injected directly into mice or DCs loaded with the same amount of noncomplexed protein. The contribution of individual Fc gammaRs to Ag presentation, T cell response induction, and induction of tumor protection was assessed. We show that Fc gammaRI and Fc gammaRIII are capable of enhancing MHC class I-restricted Ag presentation to CD8+ T cells in vitro and that these activating Fc gammaRs on DCs are required for efficient priming of Ag-specific CD8+ cells in vivo and induction of tumor protection. These findings show that targeting ICs via the activating Fc gammaRs to DCs in vitro is superior to direct IC vaccination to induce protective tumor immunity in vivo.
Collapse
Affiliation(s)
- Danita H Schuurhuis
- Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, The Netherlands
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Fang J, Wang G, Yang Q, Song J, Wang Y, Wang L. The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model. Vaccine 2006; 23:4860-6. [PMID: 16029917 DOI: 10.1016/j.vaccine.2005.05.024] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2004] [Accepted: 05/16/2005] [Indexed: 12/28/2022]
Abstract
The tumor specific antigen epitope melanoma antigen A1(161--169) (MAGE-A1(161--169)) was displayed on the major protein (p VIII) of the filamentous bacteriophage (fd). The immune responses of the phage display particles expressing MAGE-A1(161--169) in mice were studied. Using phage display particles as vaccine was effective in affording protection from tumor growth, inducing growth control of established tumors and prolonging survival of tumor-bearing mice. The hybrid phage particles elicited MAGE-A1(161--169) specific CTL responses, NK activity and DTH. Our results showed that the phage display particles might be a new vaccine candidate for tumor-associated antigen epitope in cancer immunotherapy.
Collapse
Affiliation(s)
- Jinbo Fang
- School of Life Sciences, Northeast Normal University, 5268 Renmin Street, Nanguan District, Changchun 130024, PR China
| | | | | | | | | | | |
Collapse
|
32
|
Bettosini F, Fiorillo MT, Magnacca A, Leone L, Torrisi MR, Sorrentino R. The C terminus of the nucleoprotein of influenza A virus delivers antigens transduced by Tat to the trans-golgi network and promotes an efficient presentation through HLA class I. J Virol 2006; 79:15537-46. [PMID: 16306624 PMCID: PMC1316004 DOI: 10.1128/jvi.79.24.15537-15546.2005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Cytotoxic T lymphocytes (CTLs) are the most powerful weapon of the immune system to eliminate cells infected by intracellular parasites or tumors. However, very often, escape mechanisms overcome CTL immune surveillance by impairing the classical HLA class I antigen-processing pathway. Here, we describe a strategy for CTL activation based on the ability of Tat to mediate transcellular delivery of viral proteins encompassing HLA class I-restricted epitopes. In this system, the recombinant protein TAT-NpFlu containing the transduction domain of Tat of human immunodeficiency virus type 1 fused to the amino acid region 301 to 498 of the nucleoprotein of influenza A virus is proven to sensitize different human cells to lysis by HLA-B27-restricted, Flu 383-391-specific CTL lines. The fusion protein is processed very effectively, since a comparable biological effect is obtained with an amount of protein between 1 and 2 orders of magnitude lower than that of the synthetic peptide. Interestingly, while part of TAT-NpFlu undergoes fast and productive cleavage, a large amount of it remains intact for up to 24 h. Confocal microscopy shows that TAT-NpFlu accumulates in the trans-Golgi network (TGN), where it starts to be detectable 1 h after transduction. Using TAT-NpFlu mutants and hybrid constructs, we demonstrate that enrichment in the TGN occurs only when the carboxy-terminal region of NpFlu (amino acids 400 to 498) is present. These data disclose an unconventional route for presentation of epitopes restricted for HLA class I molecules.
Collapse
Affiliation(s)
- Francesca Bettosini
- Department of Cell Biology and Development, University of Rome La Sapienza, Via dei Sardi 70, 00185 Rome, Italy
| | | | | | | | | | | |
Collapse
|
33
|
|
34
|
Chromik J, Schnürer E, Georg Meyer R, Wehler T, Tüting T, Wölfel T, Huber C, Herr W. Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes. J Immunol Methods 2006; 308:77-89. [PMID: 16336973 DOI: 10.1016/j.jim.2005.09.021] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2004] [Revised: 08/08/2005] [Accepted: 09/20/2005] [Indexed: 11/22/2022]
Abstract
The design and successful clinical implementation of cancer vaccines targeting the induction of T-cell mediated immunity is a rapidly evolving field that is hampered by an empirical selection of antigen and adjuvant. In particular, vaccines using defined tumor-associated peptide epitopes elicit only a restricted T-cell repertoire in a minority of patients. In this regard, vaccines comprising the whole spectrum of antigens presented by individual autologous tumors would be advantageous. In an in vitro model, we evaluated the capacity of naturally processed Epstein-Barr virus-transformed B-lymphoblastoid-cell line (LCL)-derived peptides to activate virus-specific CD8+ T cells of seropositive healthy individuals. While bulk peptides obtained by mild acid elution from LCL contained multiple T-cell epitopes, this complex mixture of peptides was poorly immunogenic, even when presented by mature dendritic cells (DC). Pretreatment of DC with proteasome inhibitors strongly enhanced the immunogenicity of single viral synthetic as well as bulk LCL peptides. This was most likely achieved by facilitating the loading of exogenous epitopes onto DC-associated HLA-class I complexes in the face of significant inter-peptide competition for such loading. Our results suggest that proteasome inhibitors may be used to increase the antigenicity of mature DC pulsed with exogenous synthetic or naturally processed peptide epitopes in vaccination trials.
Collapse
Affiliation(s)
- Jörg Chromik
- Department of Medicine III, Hematology and Oncology, Johannes Gutenberg-University of Mainz, Langenbeckstrasse 1, D-55101 Mainz, Germany
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Garbi N, Tanaka S, van den Broek M, Momburg F, Hämmerling GJ. Accessory molecules in the assembly of major histocompatibility complex class I/peptide complexes: how essential are they for CD8+ T-cell immune responses? Immunol Rev 2005; 207:77-88. [PMID: 16181328 DOI: 10.1111/j.0105-2896.2005.00303.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Assembly of major histocompatibility complex (MHC) class I molecules in the endoplasmic reticulum is a highly coordinated process that results in abundant class I/peptide complexes at the cell surface for recognition by CD8(+) T cells and natural killer cells. During the assembly process, a number of chaperones and accessory molecules, such as transporter associated with antigen processing, tapasin, ER60, and calreticulin, assist newly synthesized class I molecules to facilitate loading of antigenic peptides and to optimize the repertoire of surface class I/peptide complexes. This review focuses on the relative importance of these accessory molecules for CD8(+) T-cell responses in vivo and discusses reasons that may help explain why some CD8(+) T-cell responses develop normally in mice deficient in components of class I assembly, despite impaired antigen presentation.
Collapse
Affiliation(s)
- Natalio Garbi
- Division of Molecular Immunology, German Cancer Research Center, Heidelberg, Germany
| | | | | | | | | |
Collapse
|
36
|
Jones LA, Salgaller ML. Therapeutic potential of dendritic-based vaccines. Expert Opin Investig Drugs 2005; 8:1007-16. [PMID: 15992102 DOI: 10.1517/13543784.8.7.1007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Involving a delicate balance of cell types, the interaction between the immune system and disease or abnormality in the human body is complex. Moreover, the mere presence of antigen and immune cells is necessary, yet insufficient to elicit immune reactivity. In order to elicit an immune response, an antigen in some form must be processed and presented to the immune system. Arguably, the most efficient antigen-presenting cell, the dendritic cell (DC), is the centre of intense investigation. The elicitation or cessation of an immune response is not a simple matter. The body must be able either to up-regulate (e.g., in the case of infectious disease) or down-regulate (e.g., in the case of transplantation) immunity to antigens located anywhere in the body. This sentinel role is capably filled via the distribution of Langerhans cells in the epidermis of the skin, and the migration of DCs throughout the lymphatic and circulatory systems. DCs are potent, as well as efficient: small numbers of cells and low levels of antigen still induce clinically relevant immunity. Lastly, they are capable of tolerance induction to self components by helping to delete self-reactive thymocytes and generating anergy in committed T-cells. Since DCs both initiate and modulate immunity, they are a component of a vast array of vaccines. This review highlights some of the intriguing basic research involving the development of DC-based therapeutics. Furthermore, whenever an area of study has progressed to human treatment, recent and on-going clinical trials are discussed.
Collapse
Affiliation(s)
- L A Jones
- Immunotherapeutics Division, Northwest Biotherapeutics, Inc. 120 Northgate Plaza, Suite 219, Seattle, WA 98125, USA
| | | |
Collapse
|
37
|
Sánchez-Cordón PJ, Núñez A, Salguero FJ, Carrasco L, Gómez-Villamandos JC. Evolution of T Lymphocytes and Cytokine Expression in Classical Swine Fever (CSF) Virus Infection. J Comp Pathol 2005; 132:249-60. [PMID: 15893983 DOI: 10.1016/j.jcpa.2004.10.002] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2004] [Accepted: 10/18/2004] [Indexed: 11/24/2022]
Abstract
This study characterized the cell-mediated immune response in pigs inoculated with the Alfort 187 isolate of classical swine fever (CSF) virus. Quantitative changes in the T-lymphocyte population (CD3(+), CD4(+) and CD8(+)) and qualitative changes in cytokine expression (IL-2, IL-4 and IFNgamma) by these cells in serum, thymus and spleen were demonstrated. These changes coincided spatially and temporally with previously described quantitative and qualitative changes in monocyte-macrophage populations, thus demonstrating the contribution of the two cell populations to lymphoid depletion. Moreover, examination of cytokine expression in thymus and spleen samples revealed a type 1 cell-mediated immune response in the early and middle stages of the experiment, giving way to a type 2 immune response towards the end of the experiment; these findings, which accorded with the serological results and lymphopenia, may influence the delayed humoral response characteristic of CSF.
Collapse
Affiliation(s)
- P J Sánchez-Cordón
- Departamento de Anatomía y Anatomía Patológica Comparadas, Facultad de Veterinaria, Universidad de Córdoba, Edificio de Sanidad Animal, Campus de Rabanales, 14014 Córdoba, Spain
| | | | | | | | | |
Collapse
|
38
|
Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 2005; 82:506-16. [PMID: 15479436 DOI: 10.1111/j.0818-9641.2004.01271.x] [Citation(s) in RCA: 141] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Although vaccines have been highly successful in preventing and treating many infectious diseases (including smallpox, polio and diphtheria) diseases prevalent in the developing world such as malaria and HIV, that suppress the host immune system, require new, multiple strategies that will be defined by our growing understanding of specific immune activation. The definition of adjuvants, previously thought of as any substance that enhanced the immunogenicity of antigen, could now include soluble mediators and antigenic carriers that interact with surface molecules present on DC (e.g. LPS, Flt3L, heat shock protein) particulate antigens which are taken up by mechanisms available to APC but not other cell types (e.g. immunostimulatory complexes, latex, polystyrene particles) and viral/bacterial vectors that infect antigen presenting cells (e.g. vaccinia, lentivirus, adenovirus). These approaches, summarized herein, have shown potential in vaccinating against disease in animal models, and in some cases in humans. Of these, particle-antigen conjugates provide rapid formulation of the vaccine, easy storage and wide application, with both carrier and adjuvant functions that activate DC. Combined vaccines of the future could use adjuvants such as virus-like particles and particles targeted towards a predominant cellular type or immune response, with target cell activation enhanced by growth factors or maturation signals prior to, or during immunization. Collectively, these new additions to adjuvant technology provide opportunities for more specific immune regulation than previously available.
Collapse
Affiliation(s)
- Anita Gamvrellis
- Vaccine Development and Infectious Diseases Unit, The Austin Research Institute, Austin Hospital, Studley Road, Heidelberg, Victoria 3084, Australia
| | | | | | | | | | | |
Collapse
|
39
|
Cheadle EJ, O'Donnell D, Selby PJ, Jackson AM. Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun 2005; 73:784-94. [PMID: 15664917 PMCID: PMC546964 DOI: 10.1128/iai.73.2.784-794.2005] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Mycobacteria expressing recombinant antigens are already being developed as vaccines against both infections and tumors. Little is known about how dendritic cells might process such antigens. Two different mycobacterial species, the fast-growing Mycobacterium smegmatis and the slow-growing M. bovis M. bovis BCG, were engineered to express a model tumor antigen, the K(b)-restricted dominant cytotoxic T-lymphocyte epitope OVA(257-264). Recombinant M. bovis BCG but not recombinant M. smegmatis conferred protection to mice challenged with the B16-OVA tumor cell line. We went on to investigate whether the contrast in antitumor efficacy could be due to differences in how dendritic cells process antigen from the two mycobacterial strains for class I presentation. Both strains of mycobacteria caused phenotypic maturation of dendritic cells, but recombinant M. smegmatis infection led to a greater degree of dendritic cell maturation than recombinant M. bovis BCG infection. Antigen from recombinant M. smegmatis was processed and presented as OVA(257-264) on K(b) molecules by the dendritic cell line DC2.4 but not by bone marrow-derived dendritic cells (BMDC) or splenic dendritic cells. In contrast, antigen from recombinant M. bovis BCG was presented by all three dendritic cell types as long as the mycobacteria were viable. Such presentation was dependent on proteasome function and nascent major histocompatibility complex (MHC) class I molecules in DC2.4 cells but independent of the proteasome and transporter associated with antigen processings (TAP) in BMDC and splenic dendritic cells. These data demonstrate for the first time that antigen vectored by the slow-growing M. bovis BCG but not that vectored by fast-growing, readily destroyed M. smegmatis is processed and presented on MHC class I by in vitro-generated dendritic cells, which has implications for recombinant microbial vaccine development.
Collapse
Affiliation(s)
- Eleanor J Cheadle
- Department of Medical Oncology, Paterson Institute for Cancer Research, Wilmslow Road, Manchester M20 4BX, United Kingdom.
| | | | | | | |
Collapse
|
40
|
Karim M, Feng G, Wood KJ, Bushell AR. CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005; 105:4871-7. [PMID: 15713793 DOI: 10.1182/blood-2004-10-3888] [Citation(s) in RCA: 115] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
The importance of CD25(+)CD4(+) regulatory T (Treg) cells in the control of immune responses is established, but their antigen specificity in vivo remains unclear. Understanding Treg-cell specificity requirements will be important if their potential is to be developed for immunotherapy. Pretreatment of recipient mice with donor alloantigen plus anti-CD4 antibody generates CD25(+)CD4(+) Treg cells with the capacity to prevent skin allograft rejection in adoptive transfer recipients. Here we demonstrate that, although this regulation can be antigen-specific, reactivation with the original tolerizing alloantigen allows the Treg cells to suppress rejection of third-party allografts. Aware of the limitations of alloantigen pretreatment, we asked whether graft-protective Treg cells could be generated against unrelated, nongraft antigens. We demonstrate that bystander regulation also extends to CD25(+)CD4(+) Treg cells generated in vivo by exposure to nominal antigens under anti-CD4 antibody cover. Providing these Treg cells are reexposed to the tolerizing antigens before adoptive transfer, they prevent the rejection of fully allogeneic skin grafts. That this might form the basis of a clinically relevant tolerance induction strategy is demonstrated by the fact that, when combined with subtherapeutic anti-CD8 antibody, Treg cells generated in response to nongraft antigens facilitate the acceptance of cardiac allografts in primary recipients.
Collapse
MESH Headings
- Adoptive Transfer
- Animals
- Antibodies, Monoclonal/chemistry
- Antigens/chemistry
- Bystander Effect
- CD4-Positive T-Lymphocytes/immunology
- CD8 Antigens/biosynthesis
- Enzyme-Linked Immunosorbent Assay
- Graft Rejection
- Heart Transplantation/methods
- Image Processing, Computer-Assisted
- Immune Tolerance
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Inbred CBA
- Mice, Transgenic
- Models, Biological
- RNA, Messenger/metabolism
- Receptors, Interleukin-2/biosynthesis
- Skin/metabolism
- Skin Transplantation
- T-Lymphocyte Subsets/metabolism
- T-Lymphocytes/immunology
- Time Factors
- Transplantation Tolerance
- Transplantation, Homologous
Collapse
Affiliation(s)
- Mahzuz Karim
- Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Headington, Oxford OX3 9DU, United Kingdom
| | | | | | | |
Collapse
|
41
|
Peachman KK, Rao M, Palmer DR, Zidanic M, Sun W, Alving CR, Rothwell SW. Functional microtubules are required for antigen processing by macrophages and dendritic cells. Immunol Lett 2005; 95:13-24. [PMID: 15325793 DOI: 10.1016/j.imlet.2004.05.013] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2003] [Revised: 04/24/2004] [Accepted: 05/01/2004] [Indexed: 11/20/2022]
Abstract
Antigen-presenting cells readily phagocytose antigens and channel them through various membrane-bound organelles within the cell. In previous studies, we demonstrated that macrophages concentrated and localized particulate antigens to the trans-Golgi prior to displaying the MHC-class I-antigenic peptides on the cell surface. In this study, we evaluated the importance of cytoskeletal elements in the intracellular trafficking of soluble and liposome-encapsulated ovalbumin in murine bone marrow-derived macrophages and human dendritic cells. F-actin, as identified by staining with fluorescein phalloidin, was observed at the point of contact between soluble or liposomal antigen and the cell membrane, suggesting that a rearrangement of the cytoskeleton occurs to facilitate the uptake of the antigens. Cells were incubated with colchicine, a microtubule depolymerizing agent, or paclitaxel, a microtubule polymerizing agent, before the addition of Texas Red-labeled ovalbumin or liposome-encapsulated Texas Red-labeled ovalbumin. Colchicine disrupted the trans-Golgi, whereas the trans-Golgi complexes were intact in paclitaxel treated cells. In either paclitaxel or colchicine-treated macrophages, internalized liposomal ovalbumin was not concentrated in the area of the trans-Golgi as determined by staining with fluorescent ceramide. In contrast, soluble ovalbumin was concentrated in the region of the trans-Golgi in 15% of the dendritic cells treated with paclitaxel, whereas 6% of the dendritic cells were able to concentrate liposomal antigen. In colchicine-treated dendritic cells, both soluble and liposomal antigens were internalized but did not localize to the area of the trans-Golgi. These data suggest that trafficking of soluble and liposome-encapsulated ovalbumin requires a functional microtubule-dependent translocation system.
Collapse
Affiliation(s)
- Kristina K Peachman
- Department of Membrane Biochemistry, Division of Biochemistry, Walter Reed Army Institute of Research, 503 Robert Grant Road, Silver Spring, MD 20910-7500, USA.
| | | | | | | | | | | | | |
Collapse
|
42
|
Deml L, Speth C, Dierich MP, Wolf H, Wagner R. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 2005; 42:259-77. [PMID: 15488613 DOI: 10.1016/j.molimm.2004.06.028] [Citation(s) in RCA: 108] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Several previous reports have clearly demonstrated the strong effectiveness of human immunodeficiency virus (HIV) Gag polyprotein-based virus-like particles (VLP) to stimulate humoral and cellular immune responses in complete absence of additional adjuvants. Yet, the mechanisms underlying the strong immunogenicity of these particulate antigens are still not very clear. However, current reports strongly indicate that these VLP act as "danger signals" to trigger the innate immune system and possess potent adjuvant activity to enhance the immunogenicity of per se only weakly immunogenic peptides and proteins. Here, we review the current understanding of how various particle-associated substances and other impurities may contribute to the observed immune-activating properties of these complex immunogens.
Collapse
Affiliation(s)
- Ludwig Deml
- Institute of Medical Microbiology, University of Regensburg, Franz-Josef-Straurr-Allee 11, D-93053 Regensburg, Germany.
| | | | | | | | | |
Collapse
|
43
|
Ruedl C, Schwarz K, Jegerlehner A, Storni T, Manolova V, Bachmann MF. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 2005; 79:717-24. [PMID: 15613299 PMCID: PMC538584 DOI: 10.1128/jvi.79.2.717-724.2005] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Virus-like particles (VLPs) are able to induce cytotoxic T-cell responses in the absence of infection or replication. This makes VLPs promising candidates for the development of recombinant vaccines. However, VLPs are also potent inducers of B-cell responses, and it is generally assumed that such VLP-specific antibodies interfere with the induction of protective immune responses, a phenomenon summarized as carrier suppression. In this study, we investigated the impact of preexisting VLP-specific antibodies on the induction of specific cytotoxic T-cell and Th-cell responses in mice. The data show that VLP-specific antibodies did not measurably reduce antigen presentation in vitro or in vivo. Nevertheless, T-cell priming was slightly reduced by antigen-specific antibodies; however, the overall reduction was limited and vaccination with VLPs in the presence of VLP-specific antibodies still resulted in protective T-cell responses. Thus, carrier suppression is unlikely to be a limiting factor for VLP-based T-cell vaccines.
Collapse
Affiliation(s)
- Christiane Ruedl
- Cytos Biotechnology AG, Wagistrasse 25, 8952 Schlieren-Zürich, Switzerland
| | | | | | | | | | | |
Collapse
|
44
|
Schlecht G, Loucka J, Najar H, Sebo P, Leclerc C. Antigen Targeting to CD11b Allows Efficient Presentation of CD4+ and CD8+ T Cell Epitopes and In Vivo Th1-Polarized T Cell Priming. THE JOURNAL OF IMMUNOLOGY 2004; 173:6089-97. [PMID: 15528345 DOI: 10.4049/jimmunol.173.10.6089] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Bordetella pertussis adenylate cyclase (CyaA) is an invasive bacterial toxin that delivers its N-terminal catalytic domain into the cytosol of eukaryotic cells bearing the alpha(M)beta(2) integrin (CD11b/CD18), such as myeloid dendritic cells. This allows use of engineered CyaA for targeted delivery of CD8(+) T cell epitopes into the MHC class I pathway of APC and induction of robust and protective cytotoxic responses. In this study, we demonstrate that CyaA can efficiently codeliver both a CD8(+) T cell epitope (OVA(257-264)) and a CD4(+) T cell epitope (MalE(100-114)) into, respectively, the conventional cytosolic or endocytic routes of processing of murine bone marrow-derived dendritic cells. Upon CyaA delivery, a strong potentiation of the MalE(100-114) CD4(+) T cell epitope presentation is observed as compared with the MalE protein, which depends on CyaA interaction with its CD11b receptor and its subsequent clathrin-mediated endocytosis. In vivo, CyaA induces strong and specific Th1 CD4(+) and CD8(+) T cell responses against, respectively, the MalE(100-114) and OVA(257-264) epitopes. These results underscore the potency of CyaA for design of new vaccines.
Collapse
MESH Headings
- ATP-Binding Cassette Transporters/metabolism
- Actins/metabolism
- Adenylate Cyclase Toxin/administration & dosage
- Adenylate Cyclase Toxin/genetics
- Adenylate Cyclase Toxin/immunology
- Adenylate Cyclase Toxin/metabolism
- Amino Acid Sequence
- Animals
- Antigen Presentation/genetics
- Bone Marrow Cells/enzymology
- Bone Marrow Cells/immunology
- Bone Marrow Cells/metabolism
- CD11b Antigen/metabolism
- CD4-Positive T-Lymphocytes/enzymology
- CD4-Positive T-Lymphocytes/immunology
- CD4-Positive T-Lymphocytes/metabolism
- CD8-Positive T-Lymphocytes/enzymology
- CD8-Positive T-Lymphocytes/immunology
- CD8-Positive T-Lymphocytes/metabolism
- Clathrin-Coated Vesicles/physiology
- Cytotoxicity, Immunologic/genetics
- Dendritic Cells/enzymology
- Dendritic Cells/immunology
- Dendritic Cells/metabolism
- Drug Delivery Systems/methods
- Endosomes/enzymology
- Endosomes/immunology
- Endosomes/metabolism
- Epitopes, T-Lymphocyte/genetics
- Epitopes, T-Lymphocyte/immunology
- Epitopes, T-Lymphocyte/metabolism
- Escherichia coli Proteins/administration & dosage
- Escherichia coli Proteins/genetics
- Escherichia coli Proteins/immunology
- Female
- Genes, Reporter
- Histocompatibility Antigens Class I/metabolism
- Histocompatibility Antigens Class II/metabolism
- Hybridomas
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Molecular Sequence Data
- Ovalbumin/administration & dosage
- Ovalbumin/genetics
- Ovalbumin/immunology
- Peptide Fragments/administration & dosage
- Peptide Fragments/genetics
- Peptide Fragments/immunology
- Peptide Fragments/metabolism
- Peptide Hydrolases/physiology
- Periplasmic Binding Proteins/administration & dosage
- Periplasmic Binding Proteins/genetics
- Periplasmic Binding Proteins/immunology
- Proteasome Endopeptidase Complex/metabolism
- Th1 Cells/enzymology
- Th1 Cells/immunology
- Th1 Cells/metabolism
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/immunology
- Vaccines, Synthetic/metabolism
- Vacuoles/metabolism
Collapse
Affiliation(s)
- Géraldine Schlecht
- Unité de Biologie des Régulations Immunitaires, Institut National de la Santé et de la Recherche Médicale E 352, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris cedex 15, Paris, France
| | | | | | | | | |
Collapse
|
45
|
Winau F, Kaufmann SHE, Schaible UE. Apoptosis paves the detour path for CD8 T cell activation against intracellular bacteria. Cell Microbiol 2004; 6:599-607. [PMID: 15186397 DOI: 10.1111/j.1462-5822.2004.00408.x] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Intracellular bacteria such as Mycobacterium tuberculosis primarily infect macrophages. Within these host cells, the pathogens are confined to phagosomes and their antigens are secluded from the classical MHC I presentation pathway. Moreover, macrophages fail to express certain antigen presenting molecules like CD1 proteins. As a result of this intracellular lifestyle, the pathways for the induction of MHC I- and CD1-restricted CD8 T cells by such microorganisms remain elusive. Based on recent findings in tuberculosis and salmonellosis, we propose a new detour pathway for CD8 T cell activation against intracellular bacteria through apoptotic blebs from infected macrophages. Pathogen-derived antigens including proteins and lipids are delivered from infected cells to non-infected dendritic cells. Subsequently, these professional antigen presenting cells display microbial antigens through MHC I and CD1 to T cells. Thus, cross-priming mediated by apoptotic vesicles is not just a matter of antigen distribution, but an intrinsic immunological function due to the nature of phagosomally located intracellular bacteria. We consider infection-induced apoptosis the conditio sine qua non for antigen-specific CD8 T cell activation by phagosome-enclosed pathogens. This important new function of cell death in antibacterial immunity requires consideration for rational vaccine design.
Collapse
Affiliation(s)
- Florian Winau
- Max-Planck-Institute for Infection Biology, Department of Immunology, Schumannstr. 21-22, D-10117 Berlin, Germany
| | | | | |
Collapse
|
46
|
Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA, Jones CL, He LZ, Goldstein J, Wallace PK, Keler T, Endres MJ. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. THE JOURNAL OF IMMUNOLOGY 2004; 172:2845-52. [PMID: 14978085 DOI: 10.4049/jimmunol.172.5.2845] [Citation(s) in RCA: 93] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Targeting recycling endocytic receptors with specific Abs provides a means for introducing a variety of tumor-associated Ags into human dendritic cells (DCs), culminating in their efficient presentation to T cells. We have generated a human mAb (B11) against the mannose receptor that is rapidly internalized by DCs through receptor-mediated endocytosis. By genetically linking the melanoma Ag, pmel17, to Ab B11, we obtained the fully human fusion protein, B11-pmel17. Treatment of DCs with B11-pmel17 resulted in the presentation of pmel17 in the context of HLA class I and class II molecules. Thus, potent pmel17-specific T cells were cytotoxic toward gp100(+) HLA-matched melanoma targets, but not HLA-mismatched melanoma or gp100(-) nonmelanoma tumor lines. Importantly, competitive inhibition of lysis of an otherwise susceptible melanoma cell line by cold targets pulsed with known gp100 CD8 T cell epitopes as well as a dose-dependent proliferative response to Th epitopes demonstrates that DCs can process targeted Ag for activation of cytotoxic as well as helper arms of the immune response. Thus, the specific targeting of soluble exogenous tumor Ag to the DC mannose receptor directly contributes to the generation of multiple HLA-restricted Ag-specific T cell responses.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal/genetics
- Antibodies, Monoclonal/pharmacology
- Antibody Specificity/genetics
- Antigens, Neoplasm/genetics
- Antigens, Neoplasm/immunology
- Binding Sites, Antibody/genetics
- Binding, Competitive/genetics
- Binding, Competitive/immunology
- Cell Differentiation/genetics
- Cell Differentiation/immunology
- Cell Line, Transformed
- Cytotoxicity, Immunologic/genetics
- Dendritic Cells/cytology
- Dendritic Cells/immunology
- Dendritic Cells/metabolism
- Epitopes, T-Lymphocyte/immunology
- Gene Targeting/methods
- HLA Antigens/metabolism
- HLA Antigens/physiology
- HLA-A2 Antigen/metabolism
- HLA-A2 Antigen/physiology
- HLA-D Antigens/physiology
- Humans
- Lectins, C-Type/genetics
- Lectins, C-Type/immunology
- Lectins, C-Type/metabolism
- Mannose Receptor
- Mannose-Binding Lectins/genetics
- Mannose-Binding Lectins/immunology
- Mannose-Binding Lectins/metabolism
- Melanoma/immunology
- Melanoma/prevention & control
- Membrane Glycoproteins/chemical synthesis
- Membrane Glycoproteins/immunology
- Mice
- Mice, Transgenic
- Molecular Sequence Data
- Neoplasm Proteins/chemical synthesis
- Neoplasm Proteins/immunology
- Proteins/genetics
- Proteins/immunology
- Proteins/physiology
- Receptors, Cell Surface/genetics
- Receptors, Cell Surface/immunology
- Receptors, Cell Surface/metabolism
- Recombinant Fusion Proteins/chemical synthesis
- Recombinant Fusion Proteins/metabolism
- T-Lymphocytes, Cytotoxic/cytology
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Cytotoxic/metabolism
- T-Lymphocytes, Helper-Inducer/immunology
- Transfection
- gp100 Melanoma Antigen
Collapse
|
47
|
Chen L, Jondal M. Endolysosomal Processing of Exogenous Antigen into Major Histocompatibility Complex Class I-Binding Peptides. Scand J Immunol 2004; 59:545-52. [PMID: 15182249 DOI: 10.1111/j.1365-3083.2004.01426.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
An alternative endolysosomal pathway has recently been suggested for the processing of MHC-I-binding peptides, and peptide/MHC-I complexes have been demonstrated in this compartment. However, it remains unclear where in the antigen-presenting cells such peptides are processed, in the endolysosomes themselves or in the proteasomal complex. Here, we have investigated this using monoclonal antibodies specific for the immunodominant SIINFEKL/Kb complex (25-D1) or for the carbohydrate part of Db- or Kb-binding glycopeptides in combination with inhibitors for classical and endolysosomal MHC-I-processing pathways. Alternative processing was detected in both wt and TAP1(-/-) immature DC (iDC) as the expression of SIINFEKL/Kb complexes on the surface of OVA-treated cells in the presence of Brefeldin A (BFA) or lactacystin and their absence in the presence of the lysosomotropic amines ammonium chloride, chloroquine and methylamine. Internalized Db- and Kb-binding glycopeptides, detected with high specificity using an anti-galabiose (Gal2) monoclonal antibody, were found to appear on the cell surface of BFA-treated cells after intracellular MHC-I-binding. Peptide exchange in Kb was demonstrated as the gradual appearance of SIINFEKL/Kb complexes on BFA-treated cells which earlier had been saturated with another Kb-binding peptide. Our data support the presence of a fully functional endolysosomal processing pathway in iDC guided by the chaperone function of MHC-I molecules.
Collapse
Affiliation(s)
- L Chen
- Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden
| | | |
Collapse
|
48
|
de Arruda LB, Chikhlikar PR, August JT, Marques ETA. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 2004; 112:126-33. [PMID: 15129672 PMCID: PMC1782456 DOI: 10.1111/j.1365-2567.2004.01823.x] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2003] [Revised: 11/06/2003] [Accepted: 01/06/2004] [Indexed: 12/25/2022] Open
Abstract
Antigen presentation by major histocompatibility complex type II (MHC II) molecules and activation of CD4+ helper T cells are critical for the generation of immunological memory. We previously described a DNA vaccine encoding human immunodeficiency virus-1 p55Gag as a chimera with the lysosome-associated membrane protein (LAMP/gag). The LAMP/gag chimera protein traffics to the MHC II compartment of transfected cells and elicits enhanced immune responses as compared to a DNA vaccine encoding native gag not targeted to the MHC II compartment. We have now investigated the long-term responses of immunized mice and show that the LAMP/gag DNA vaccine promotes long-lasting B cell- and CD4+ and CD8+ T-cell memory responses induced by DNA encoding non-targeted Gag decay rapidly and elicit very low or undetectable levels of gag DNA is sufficient to generate T-cell memory. Following this initial priming immunization with LAMP/gag DNA, booster immunizations with native gag DNA or the LAMP/gag chimera are equally efficient in eliciting B- and T-cell secondary responses, results in accordance with observations that secondary expansion of CD8+ cells in the boost phase does not require additional CD4+ help. These findings underscore the significance of targeting DNA-encoded vaccine antigens to the MHC II processing compartments for induction of long-term immunological memory.
Collapse
|
49
|
Chakrabarti R, Chang Y, Song K, Prud'homme GJ. Plasmids encoding membrane-bound IL-4 or IL-12 strongly costimulate DNA vaccination against carcinoembryonic antigen (CEA). Vaccine 2004; 22:1199-205. [PMID: 15003648 DOI: 10.1016/j.vaccine.2003.09.023] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2003] [Revised: 09/24/2003] [Accepted: 09/24/2003] [Indexed: 11/27/2022]
Abstract
Vaccination with plasmids encoding an antigen of interest (DNA vaccination) is a new strategy to achieve effective immunization against many agents. DNA vaccination can be ameliorated by co-administration of plasmids encoding a cytokine. Thus far, only plasmids encoding soluble cytokines have been used for this purpose. However, these plasmids can induce release of cytokines into the circulation and could potentially cause many undesirable effects. We undertook this study to determine whether membrane-bound cytokines, which would restrict their localization at the site of administration, can act as immunoadjuvants. We and others have previously shown that plasmids encoding soluble IL-4 and IL-12 are effective adjuvants for DNA vaccination. In this study, we demonstrate that DNA co-vaccination with membrane-bound IL-4 (mbIL-4) or membrane-bound IL-12 (mbIL-12) both enhance anti-CEA immunity, as detected by in vitro and in vivo assays. Mice co-injected with plasmids encoding CEA and either type of membrane-bound cytokine rejected transplanted CEA-positive tumor cells strongly. Notably, unlike secreted IL-4, mbIL-4 was the most effective adjuvant for anti-tumor immunity. This study demonstrates that membrane-bound cytokines are suitable adjuvants for DNA vaccination.
Collapse
Affiliation(s)
- Rabindranath Chakrabarti
- Department of Laboratory Medicine and Pathobiology, St. Micheal's Hospital and University of Toronto, 30 Bond Street, Toronto, Ont., Canada M5B 1W8
| | | | | | | |
Collapse
|
50
|
Lorin C, Mollet L, Delebecque F, Combredet C, Hurtrel B, Charneau P, Brahic M, Tangy F. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004; 78:146-57. [PMID: 14671096 PMCID: PMC303376 DOI: 10.1128/jvi.78.1.146-157.2004] [Citation(s) in RCA: 110] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The anchored and secreted forms of the human immunodeficiency virus type 1 (HIV-1) 89.6 envelope glycoprotein, either complete or after deletion of the V3 loop, were expressed in a cloned attenuated measles virus (MV) vector. The recombinant viruses grew as efficiently as the parental virus and expressed high levels of the HIV protein. Expression was stable during serial passages. The immunogenicity of these recombinant vectors was tested in mice susceptible to MV and in macaques. High titers of antibodies to both MV and HIV-Env were obtained after a single injection in susceptible mice. These antibodies neutralized homologous SHIV89.6p virus, as well as several heterologous HIV-1 primary isolates. A gp160 mutant in which the V3 loop was deleted induced antibodies that neutralized heterologous viruses more efficiently than antibodies induced by the native envelope protein. A high level of CD8+ and CD4+ cells specific for HIV gp120 was also detected in MV-susceptible mice. Furthermore, recombinant MV was able to raise immune responses against HIV in mice and macaques with a preexisting anti-MV immunity. Therefore, recombinant MV vaccines inducing anti-HIV neutralizing antibodies and specific T lymphocytes responses deserve to be tested as a candidate AIDS vaccine.
Collapse
Affiliation(s)
- Clarisse Lorin
- Unité des Virus Lents, CNRS URA 1930, Unité de Physiopathologie des Infections Lentivirales, Groupe de Virologie Moléculaire et de Vectorologie, Institut Pasteur, Paris, France
| | - Lucile Mollet
- Unité des Virus Lents, CNRS URA 1930, Unité de Physiopathologie des Infections Lentivirales, Groupe de Virologie Moléculaire et de Vectorologie, Institut Pasteur, Paris, France
| | - Frédéric Delebecque
- Unité des Virus Lents, CNRS URA 1930, Unité de Physiopathologie des Infections Lentivirales, Groupe de Virologie Moléculaire et de Vectorologie, Institut Pasteur, Paris, France
| | - Chantal Combredet
- Unité des Virus Lents, CNRS URA 1930, Unité de Physiopathologie des Infections Lentivirales, Groupe de Virologie Moléculaire et de Vectorologie, Institut Pasteur, Paris, France
| | - Bruno Hurtrel
- Unité des Virus Lents, CNRS URA 1930, Unité de Physiopathologie des Infections Lentivirales, Groupe de Virologie Moléculaire et de Vectorologie, Institut Pasteur, Paris, France
| | - Pierre Charneau
- Unité des Virus Lents, CNRS URA 1930, Unité de Physiopathologie des Infections Lentivirales, Groupe de Virologie Moléculaire et de Vectorologie, Institut Pasteur, Paris, France
| | - Michel Brahic
- Unité des Virus Lents, CNRS URA 1930, Unité de Physiopathologie des Infections Lentivirales, Groupe de Virologie Moléculaire et de Vectorologie, Institut Pasteur, Paris, France
| | - Frédéric Tangy
- Unité des Virus Lents, CNRS URA 1930, Unité de Physiopathologie des Infections Lentivirales, Groupe de Virologie Moléculaire et de Vectorologie, Institut Pasteur, Paris, France
- Corresponding author. Mailing address: Unité des Virus Lents, Institut Pasteur, 28 rue du Dr Roux, 75015 Paris, France. Phone: (33) 1-45-68-87-73. Fax: (33) 1-40-61-31-67. E-mail:
| |
Collapse
|